MREO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mereo BioPharma Group PLC (MREO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has significant negative catalysts, poor financial performance, and lacks strong technical or sentiment-based signals to support a bullish outlook. The current pre-market price trend is bearish, and the company's fundamentals and market sentiment do not align with a long-term investment strategy.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 43.003, showing no clear overbought or oversold conditions. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5. The stock is trading below key pivot levels, with support at 0.361 and resistance at 0.401, suggesting a bearish trend. Pre-market price is down 0.08%, further indicating weakness.
NULL identified. The FDA's endorsement of bone mineral density (BMD) as a valid surrogate endpoint in osteoporosis could provide a potential path to market for setrusumab, but this is speculative and uncertain.
The company's Phase 3 Orbit and Cosmic studies for setrusumab failed to achieve statistical significance for primary endpoints, leading to sharp downgrades and price target reductions by analysts. Multiple class action lawsuits have been filed against the company for allegedly misleading investors about drug study results. Hedge funds and insiders are neutral, with no significant trading trends. Financial performance is weak, with declining net income and EPS.
In Q3 2025, revenue remained at 0, showing no growth. Net income dropped by 53.18% YoY to -$7,024,000, and EPS declined by 50% YoY to -$0.01. Gross margin remained flat at 73.4%. Overall, the company is not showing signs of financial improvement.
Analysts have significantly downgraded the stock. Cantor Fitzgerald, BTIG, Baird, and Jefferies all reduced price targets drastically, citing the failure of Phase 3 trials. The probability of success for setrusumab has been lowered to as low as 5% by some analysts, and the company's pipeline is considered risky and dependent on uncertain partnerships.
